Treatment of fibrosis with interleukin-11 antibody
AssigneesSingapore Health Services Pte Ltd, National University of Singapore
InventorsStuart Alexander Cook, Sebastian Schaefer
Life of this patent
Estimating the term…
Abstract
Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
Claims11
A method of treating a disease or condition characterised by fibrosis of the skin in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
A method of treating a disease or condition characterised by fibrosis selected from the group consisting of:
- scleroderma, nephrogenic systemic fibrosis and cutis keloid in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
Dependencies are inferred from the claim text.